CPT code 0174U identifies a proprietary LC–MS/MS Targeted Proteomic Assay from OncoOmicDx Laboratory that quantifies 30 proteins in FFPE tissue of solid organ tumors. As a PLA (Proprietary Laboratory Analyses) code, 0174U applies exclusively to a single, manufacturer-specific laboratory test, which has implications for coding specificity, payer recognition, and clinical reporting. Nationally, PLA codes like 0174U are important for capturing advanced, proprietary diagnostics used in oncology and precision medicine.

Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code's clinical purpose, typical site of service, and service type, along with payer coverage considerations and common billing modifiers. The publication provides benchmarks and policy context relevant to proprietary laboratory tests, including coding guidance, payer coverage patterns, and operational considerations for laboratories and billing teams.

This summary is intended for a national audience of laboratory managers, coding and billing professionals, and oncology clinicians seeking a clear explanation of what CPT code 0174U represents and how it is positioned within current diagnostic and reimbursement frameworks.